Document is current

Article History

Received: 18 August 2023

Accepted: 3 November 2023

First Online: 17 December 2023

Declarations

:

: SK received speaker honoraria from GSK outside the submitted work. WG has been on advisory boards of SpringworksTx, PTC Therapeutics and Agenus, honoraria were paid to the institute; she has obtained a research grant from Eli Lilly (to the institute). NE received grants for the conduct of investigator driven studies from Ipsen and Astellas. NS provided consultation or attended advisory boards for Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Incyte, Luszana. NS received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda. All outside the submitted work, all payment to the Netherlands Cancer Institute. The other authors declare no potential conflicts of interest.